Rivaroxaban for the treatment of venous thromboembolism. The SWIss Venous ThromboEmbolism Registry (SWIVTER)
We investigated three-month clinical outcomes in patients with venous thromboembolism (VTE) treated with rivaroxaban or conventional anticoagulation in routine clinical practice. Between November 2012 and February 2015, 2,062 consecutive patients with VTE from 11 acute care hospitals in Switzerland...
Gespeichert in:
| Veröffentlicht in: | Thrombosis and haemostasis 2016-09, Vol.116 (3), p.472-479 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 479 |
|---|---|
| container_issue | 3 |
| container_start_page | 472 |
| container_title | Thrombosis and haemostasis |
| container_volume | 116 |
| creator | Kucher, Nils Aujesky, Drahomir Beer, Jürg H Mazzolai, Lucia Baldi, Thomas Banyai, Martin Hayoz, Daniel Kaeslin, Thomas Korte, Wolfgang Escher, Robert Husmann, Marc Frauchiger, Beat Baumgartner, Iris Spirk, David |
| description | We investigated three-month clinical outcomes in patients with venous thromboembolism (VTE) treated with rivaroxaban or conventional anticoagulation in routine clinical practice. Between November 2012 and February 2015, 2,062 consecutive patients with VTE from 11 acute care hospitals in Switzerland were enrolled in the SWIss Venous ThromboEmbolism Registry (SWIVTER). Overall, 417 (20 %) patients were treated with rivaroxaban. In comparison to 1,645 patients on conventional anticoagulation, patients on rivaroxaban were younger (56 ± 18 vs. 65 ± 17 years; p |
| doi_str_mv | 10.1160/TH16-03-0209 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1160_TH16_03_0209</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>27346301</sourcerecordid><originalsourceid>FETCH-LOGICAL-c248t-a35e452fa25a1c0a3d7198a3a628876775959d3b23d08e549fafd52c7cbe55fc3</originalsourceid><addsrcrecordid>eNo90M9LwzAUwPEgipvTm2fJUcHM_E5zlFHdYCDMOr2VtE20si4j6Yb77-3o9PB48PjwDl8ArgkeEyLxQzYlEmGGMMX6BAypkArJRH-cgiFmHCNJuRiAixi_MSaSa3EOBlQxLhkmQ7Ba1DsT_I8pzBo6H2D7ZWEbrGkbu26hd3Bn134bu3vwTeFtN6s6NmOYdfD1fRYjXPYi60V6FHBhP-vYhj287dgySxd3l-DMmVW0V8c9Am9PaTaZovnL82zyOEcl5UmLDBOWC-oMFYaU2LBKEZ0YZiRNEiWVElroihWUVTixgmtnXCVoqcrCCuFKNgL3_d8y-BiDdfkm1I0J-5zg_BAtP0TLMcsP0Tp-0_PNtmhs9Y__KrFfzv5oMA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Rivaroxaban for the treatment of venous thromboembolism. The SWIss Venous ThromboEmbolism Registry (SWIVTER)</title><source>MEDLINE</source><source>Thieme Connect Journals</source><creator>Kucher, Nils ; Aujesky, Drahomir ; Beer, Jürg H ; Mazzolai, Lucia ; Baldi, Thomas ; Banyai, Martin ; Hayoz, Daniel ; Kaeslin, Thomas ; Korte, Wolfgang ; Escher, Robert ; Husmann, Marc ; Frauchiger, Beat ; Baumgartner, Iris ; Spirk, David</creator><creatorcontrib>Kucher, Nils ; Aujesky, Drahomir ; Beer, Jürg H ; Mazzolai, Lucia ; Baldi, Thomas ; Banyai, Martin ; Hayoz, Daniel ; Kaeslin, Thomas ; Korte, Wolfgang ; Escher, Robert ; Husmann, Marc ; Frauchiger, Beat ; Baumgartner, Iris ; Spirk, David</creatorcontrib><description><![CDATA[We investigated three-month clinical outcomes in patients with venous thromboembolism (VTE) treated with rivaroxaban or conventional anticoagulation in routine clinical practice. Between November 2012 and February 2015, 2,062 consecutive patients with VTE from 11 acute care hospitals in Switzerland were enrolled in the SWIss Venous ThromboEmbolism Registry (SWIVTER). Overall, 417 (20 %) patients were treated with rivaroxaban. In comparison to 1,645 patients on conventional anticoagulation, patients on rivaroxaban were younger (56 ± 18 vs. 65 ± 17 years; p<0.001), less often had pulmonary embolism (38 % vs 66 %; p<0.001), hypertension (26 % vs 41 %; p<0.001), cancer (10 % vs 28 %; p<0.001), congestive heart failure (10 % vs 17 %; p=0.001), diabetes (8 % vs 15 %; p<0.001), chronic lung disease (7 % vs 13 %; p=0.001), renal insufficiency (7 % vs 13 %; p=0.001), recent surgery (7 % vs 14 %; p<0.001), and acute coronary syndrome (1 % vs 4 %; p=0.009). VTE reperfusion therapy was more frequently used (28 % vs 9 %; p<0.001) and indefinite-duration anticoagulation treatment less often planned (26 % vs 39 %; p<0.001), respectively. In the propensity score-adjusted population, the risk of recurrent VTE was similar in patients on rivaroxaban vs conventional anticoagulation (1.2 % vs 2.1 %, hazard ratio [HR] 0.55, 95 % confidence interval [CI] 0.18-1.65; p=0.29); the risk of major bleeding was also similar, respectively (0.5 % vs 0.5 %, HR 1.00, 95 %CI 0.14-7.07; p=1.00). Conventional anticoagulation is still frequently used for the treatment of VTE, particularly in the elderly and those with comorbidities. Early clinical outcomes were comparable between propensity score-adjusted patient populations on rivaroxaban and conventional anticoagulation.]]></description><identifier>ISSN: 0340-6245</identifier><identifier>EISSN: 2567-689X</identifier><identifier>DOI: 10.1160/TH16-03-0209</identifier><identifier>PMID: 27346301</identifier><language>eng</language><publisher>Germany</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Anticoagulants - adverse effects ; Anticoagulants - therapeutic use ; Factor Xa Inhibitors - adverse effects ; Factor Xa Inhibitors - therapeutic use ; Female ; Hemorrhage - chemically induced ; Humans ; Male ; Middle Aged ; Pulmonary Embolism - drug therapy ; Registries ; Retrospective Studies ; Rivaroxaban - adverse effects ; Rivaroxaban - therapeutic use ; Switzerland ; Thrombolytic Therapy ; Treatment Outcome ; Venous Thromboembolism - drug therapy</subject><ispartof>Thrombosis and haemostasis, 2016-09, Vol.116 (3), p.472-479</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c248t-a35e452fa25a1c0a3d7198a3a628876775959d3b23d08e549fafd52c7cbe55fc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27346301$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kucher, Nils</creatorcontrib><creatorcontrib>Aujesky, Drahomir</creatorcontrib><creatorcontrib>Beer, Jürg H</creatorcontrib><creatorcontrib>Mazzolai, Lucia</creatorcontrib><creatorcontrib>Baldi, Thomas</creatorcontrib><creatorcontrib>Banyai, Martin</creatorcontrib><creatorcontrib>Hayoz, Daniel</creatorcontrib><creatorcontrib>Kaeslin, Thomas</creatorcontrib><creatorcontrib>Korte, Wolfgang</creatorcontrib><creatorcontrib>Escher, Robert</creatorcontrib><creatorcontrib>Husmann, Marc</creatorcontrib><creatorcontrib>Frauchiger, Beat</creatorcontrib><creatorcontrib>Baumgartner, Iris</creatorcontrib><creatorcontrib>Spirk, David</creatorcontrib><title>Rivaroxaban for the treatment of venous thromboembolism. The SWIss Venous ThromboEmbolism Registry (SWIVTER)</title><title>Thrombosis and haemostasis</title><addtitle>Thromb Haemost</addtitle><description><![CDATA[We investigated three-month clinical outcomes in patients with venous thromboembolism (VTE) treated with rivaroxaban or conventional anticoagulation in routine clinical practice. Between November 2012 and February 2015, 2,062 consecutive patients with VTE from 11 acute care hospitals in Switzerland were enrolled in the SWIss Venous ThromboEmbolism Registry (SWIVTER). Overall, 417 (20 %) patients were treated with rivaroxaban. In comparison to 1,645 patients on conventional anticoagulation, patients on rivaroxaban were younger (56 ± 18 vs. 65 ± 17 years; p<0.001), less often had pulmonary embolism (38 % vs 66 %; p<0.001), hypertension (26 % vs 41 %; p<0.001), cancer (10 % vs 28 %; p<0.001), congestive heart failure (10 % vs 17 %; p=0.001), diabetes (8 % vs 15 %; p<0.001), chronic lung disease (7 % vs 13 %; p=0.001), renal insufficiency (7 % vs 13 %; p=0.001), recent surgery (7 % vs 14 %; p<0.001), and acute coronary syndrome (1 % vs 4 %; p=0.009). VTE reperfusion therapy was more frequently used (28 % vs 9 %; p<0.001) and indefinite-duration anticoagulation treatment less often planned (26 % vs 39 %; p<0.001), respectively. In the propensity score-adjusted population, the risk of recurrent VTE was similar in patients on rivaroxaban vs conventional anticoagulation (1.2 % vs 2.1 %, hazard ratio [HR] 0.55, 95 % confidence interval [CI] 0.18-1.65; p=0.29); the risk of major bleeding was also similar, respectively (0.5 % vs 0.5 %, HR 1.00, 95 %CI 0.14-7.07; p=1.00). Conventional anticoagulation is still frequently used for the treatment of VTE, particularly in the elderly and those with comorbidities. Early clinical outcomes were comparable between propensity score-adjusted patient populations on rivaroxaban and conventional anticoagulation.]]></description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anticoagulants - adverse effects</subject><subject>Anticoagulants - therapeutic use</subject><subject>Factor Xa Inhibitors - adverse effects</subject><subject>Factor Xa Inhibitors - therapeutic use</subject><subject>Female</subject><subject>Hemorrhage - chemically induced</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pulmonary Embolism - drug therapy</subject><subject>Registries</subject><subject>Retrospective Studies</subject><subject>Rivaroxaban - adverse effects</subject><subject>Rivaroxaban - therapeutic use</subject><subject>Switzerland</subject><subject>Thrombolytic Therapy</subject><subject>Treatment Outcome</subject><subject>Venous Thromboembolism - drug therapy</subject><issn>0340-6245</issn><issn>2567-689X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo90M9LwzAUwPEgipvTm2fJUcHM_E5zlFHdYCDMOr2VtE20si4j6Yb77-3o9PB48PjwDl8ArgkeEyLxQzYlEmGGMMX6BAypkArJRH-cgiFmHCNJuRiAixi_MSaSa3EOBlQxLhkmQ7Ba1DsT_I8pzBo6H2D7ZWEbrGkbu26hd3Bn134bu3vwTeFtN6s6NmOYdfD1fRYjXPYi60V6FHBhP-vYhj287dgySxd3l-DMmVW0V8c9Am9PaTaZovnL82zyOEcl5UmLDBOWC-oMFYaU2LBKEZ0YZiRNEiWVElroihWUVTixgmtnXCVoqcrCCuFKNgL3_d8y-BiDdfkm1I0J-5zg_BAtP0TLMcsP0Tp-0_PNtmhs9Y__KrFfzv5oMA</recordid><startdate>20160901</startdate><enddate>20160901</enddate><creator>Kucher, Nils</creator><creator>Aujesky, Drahomir</creator><creator>Beer, Jürg H</creator><creator>Mazzolai, Lucia</creator><creator>Baldi, Thomas</creator><creator>Banyai, Martin</creator><creator>Hayoz, Daniel</creator><creator>Kaeslin, Thomas</creator><creator>Korte, Wolfgang</creator><creator>Escher, Robert</creator><creator>Husmann, Marc</creator><creator>Frauchiger, Beat</creator><creator>Baumgartner, Iris</creator><creator>Spirk, David</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20160901</creationdate><title>Rivaroxaban for the treatment of venous thromboembolism. The SWIss Venous ThromboEmbolism Registry (SWIVTER)</title><author>Kucher, Nils ; Aujesky, Drahomir ; Beer, Jürg H ; Mazzolai, Lucia ; Baldi, Thomas ; Banyai, Martin ; Hayoz, Daniel ; Kaeslin, Thomas ; Korte, Wolfgang ; Escher, Robert ; Husmann, Marc ; Frauchiger, Beat ; Baumgartner, Iris ; Spirk, David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c248t-a35e452fa25a1c0a3d7198a3a628876775959d3b23d08e549fafd52c7cbe55fc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anticoagulants - adverse effects</topic><topic>Anticoagulants - therapeutic use</topic><topic>Factor Xa Inhibitors - adverse effects</topic><topic>Factor Xa Inhibitors - therapeutic use</topic><topic>Female</topic><topic>Hemorrhage - chemically induced</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pulmonary Embolism - drug therapy</topic><topic>Registries</topic><topic>Retrospective Studies</topic><topic>Rivaroxaban - adverse effects</topic><topic>Rivaroxaban - therapeutic use</topic><topic>Switzerland</topic><topic>Thrombolytic Therapy</topic><topic>Treatment Outcome</topic><topic>Venous Thromboembolism - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kucher, Nils</creatorcontrib><creatorcontrib>Aujesky, Drahomir</creatorcontrib><creatorcontrib>Beer, Jürg H</creatorcontrib><creatorcontrib>Mazzolai, Lucia</creatorcontrib><creatorcontrib>Baldi, Thomas</creatorcontrib><creatorcontrib>Banyai, Martin</creatorcontrib><creatorcontrib>Hayoz, Daniel</creatorcontrib><creatorcontrib>Kaeslin, Thomas</creatorcontrib><creatorcontrib>Korte, Wolfgang</creatorcontrib><creatorcontrib>Escher, Robert</creatorcontrib><creatorcontrib>Husmann, Marc</creatorcontrib><creatorcontrib>Frauchiger, Beat</creatorcontrib><creatorcontrib>Baumgartner, Iris</creatorcontrib><creatorcontrib>Spirk, David</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Thrombosis and haemostasis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kucher, Nils</au><au>Aujesky, Drahomir</au><au>Beer, Jürg H</au><au>Mazzolai, Lucia</au><au>Baldi, Thomas</au><au>Banyai, Martin</au><au>Hayoz, Daniel</au><au>Kaeslin, Thomas</au><au>Korte, Wolfgang</au><au>Escher, Robert</au><au>Husmann, Marc</au><au>Frauchiger, Beat</au><au>Baumgartner, Iris</au><au>Spirk, David</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rivaroxaban for the treatment of venous thromboembolism. The SWIss Venous ThromboEmbolism Registry (SWIVTER)</atitle><jtitle>Thrombosis and haemostasis</jtitle><addtitle>Thromb Haemost</addtitle><date>2016-09-01</date><risdate>2016</risdate><volume>116</volume><issue>3</issue><spage>472</spage><epage>479</epage><pages>472-479</pages><issn>0340-6245</issn><eissn>2567-689X</eissn><abstract><![CDATA[We investigated three-month clinical outcomes in patients with venous thromboembolism (VTE) treated with rivaroxaban or conventional anticoagulation in routine clinical practice. Between November 2012 and February 2015, 2,062 consecutive patients with VTE from 11 acute care hospitals in Switzerland were enrolled in the SWIss Venous ThromboEmbolism Registry (SWIVTER). Overall, 417 (20 %) patients were treated with rivaroxaban. In comparison to 1,645 patients on conventional anticoagulation, patients on rivaroxaban were younger (56 ± 18 vs. 65 ± 17 years; p<0.001), less often had pulmonary embolism (38 % vs 66 %; p<0.001), hypertension (26 % vs 41 %; p<0.001), cancer (10 % vs 28 %; p<0.001), congestive heart failure (10 % vs 17 %; p=0.001), diabetes (8 % vs 15 %; p<0.001), chronic lung disease (7 % vs 13 %; p=0.001), renal insufficiency (7 % vs 13 %; p=0.001), recent surgery (7 % vs 14 %; p<0.001), and acute coronary syndrome (1 % vs 4 %; p=0.009). VTE reperfusion therapy was more frequently used (28 % vs 9 %; p<0.001) and indefinite-duration anticoagulation treatment less often planned (26 % vs 39 %; p<0.001), respectively. In the propensity score-adjusted population, the risk of recurrent VTE was similar in patients on rivaroxaban vs conventional anticoagulation (1.2 % vs 2.1 %, hazard ratio [HR] 0.55, 95 % confidence interval [CI] 0.18-1.65; p=0.29); the risk of major bleeding was also similar, respectively (0.5 % vs 0.5 %, HR 1.00, 95 %CI 0.14-7.07; p=1.00). Conventional anticoagulation is still frequently used for the treatment of VTE, particularly in the elderly and those with comorbidities. Early clinical outcomes were comparable between propensity score-adjusted patient populations on rivaroxaban and conventional anticoagulation.]]></abstract><cop>Germany</cop><pmid>27346301</pmid><doi>10.1160/TH16-03-0209</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0340-6245 |
| ispartof | Thrombosis and haemostasis, 2016-09, Vol.116 (3), p.472-479 |
| issn | 0340-6245 2567-689X |
| language | eng |
| recordid | cdi_crossref_primary_10_1160_TH16_03_0209 |
| source | MEDLINE; Thieme Connect Journals |
| subjects | Adult Aged Aged, 80 and over Anticoagulants - adverse effects Anticoagulants - therapeutic use Factor Xa Inhibitors - adverse effects Factor Xa Inhibitors - therapeutic use Female Hemorrhage - chemically induced Humans Male Middle Aged Pulmonary Embolism - drug therapy Registries Retrospective Studies Rivaroxaban - adverse effects Rivaroxaban - therapeutic use Switzerland Thrombolytic Therapy Treatment Outcome Venous Thromboembolism - drug therapy |
| title | Rivaroxaban for the treatment of venous thromboembolism. The SWIss Venous ThromboEmbolism Registry (SWIVTER) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T02%3A15%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rivaroxaban%20for%20the%20treatment%20of%20venous%20thromboembolism.%20The%20SWIss%20Venous%20ThromboEmbolism%20Registry%20(SWIVTER)&rft.jtitle=Thrombosis%20and%20haemostasis&rft.au=Kucher,%20Nils&rft.date=2016-09-01&rft.volume=116&rft.issue=3&rft.spage=472&rft.epage=479&rft.pages=472-479&rft.issn=0340-6245&rft.eissn=2567-689X&rft_id=info:doi/10.1160/TH16-03-0209&rft_dat=%3Cpubmed_cross%3E27346301%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/27346301&rfr_iscdi=true |